|Articles|January 15, 2002
- BioPharm International-01-01-2002
- Volume 15
- Issue 1
From the Editor: Farewell to 2001 . . . Our Biotech Odyssey Continues
Author(s)S. Anne Montgomery
by S. Anne Montgomery
Advertisement
Articles in this issue
over 23 years ago
Inside Washington: Biotechnology in the Limelight, the Year Aheadover 23 years ago
Your Vested Interests: The War of the Westover 23 years ago
Statistics for Laboratory Method Comparison Studiesover 23 years ago
Liposomes (a Review): Part Two, Drug Delivery Systemsover 23 years ago
Information Age AuditsNewsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Advertisement
Advertisement
Advertisement
Trending on BioPharm International
1
Why Flexibility and Commercial Viability Must Be Built-in Early for Scaling CGTs
2
How Rentschler Biopharma’s New Platforms Aim to Accelerate Biologics Development in Asia
3
Analyzing the Safety and Scope of Next-Generation Gene Editing Platforms
4
Selecting the Right Drug Delivery Formulations to Enhance Patient-Centric Care
5
